Get the Stockscreener App
118.43
2.46%
2.59
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $118.43, with a volume of 4.48M.
It is up +2.46% in the last 24 hours and up +11.50% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$115.84
Open:
$116.9
24h Volume:
4.48M
Relative Volume:
0.32
Market Cap:
$294.22B
Revenue:
$65.00B
Net Income/Loss:
$18.26B
P/E Ratio:
16.28
EPS:
7.2751
Net Cash Flow:
$13.05B
1W Performance:
+11.03%
1M Performance:
+11.50%
6M Performance:
+48.62%
1Y Performance:
+30.80%
1-Day Range:
$116.50
$119.77
1-Week Range:
$107.10
$119.77
52-Week Range:
$73.31
$119.77
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
118.54 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
LLY
Lilly Eli Co
|
1,098.00 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
234.29 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
210.93 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
153.80 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript - Insider Monkey
Ashton Thomas Private Wealth LLC Acquires 43,047 Shares of Merck & Co., Inc. $MRK - MarketBeat
Payne Capital LLC Purchases Shares of 10,540 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. Q4 Earnings Call Highlights - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Trading Up 2.2% on Earnings Beat - MarketBeat
Merck Looks Ahead To Phase III-Rich Period As Keytruda Winds Down - Citeline News & Insights
Merck & Co Inc (MRK) Q4 2025 Earnings Call Highlights: Strong Gr - GuruFocus
AI for investors - MLQ.ai
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline - BioSpace
Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow - Benzinga
Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Merck shares dip as 2026 outlook misses Wall Street expectations - Proactive financial news
Merck’s Full Year Forecast Misses Expectations on Gardasil Woes - Bloomberg.com
Merck & Co., Inc. (NYSE:MRK) Issues FY 2026 Earnings Guidance - MarketBeat
Merck & Co., Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Merck beats on fourth quarter revenue but disappoints on outlook - Sharecast News
Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors - Chartmill
Jim Cramer on Merck & Co.: "I Think It Can Spread Out the Wealth" - Finviz
Jim Cramer on Merck & Co.: “I Think It Can Spread Out the Wealth” - Yahoo Finance UK
Merck stock dips as 2026 outlook falls short of expectations (MRK:NYSE) - Seeking Alpha
Our Q4 and full-year 2025 financial results - Merck
Merck & Co., Inc. 8-K Filing Analysis - TradingView
Merck & Co., Inc. $MRK Shares Sold by Jones Financial Companies Lllp - MarketBeat
Merck's Q4 sales rise by 5% to $16.4B - breakingthenews.net
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline - Business Wire
Where is Merck & Co. (MRK) headed according to Wall Street? - MSN
Where is Merck & Co. (MRK) Headed According to Wall Street? - Finviz
Does Merck & Co. (NYSE:MRK) Maintain Pharma Reach In S&P 500 Fund - Kalkine Media
Pfizer, Merck And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Merck & Co., Inc. (NYSE:MRK) Shares Up 2.9%Time to Buy? - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month HighHere's Why - MarketBeat
Merck Q4 2025 Earnings Preview (MRK:NYSE) - Seeking Alpha
A Look Ahead: Merck & Co's Earnings Forecast - Benzinga
Merck & Co., Inc. $MRK Shares Sold by Woodmont Investment Counsel LLC - MarketBeat
Merck (MRK) Q4 Earnings Report Preview: What To Look For - Finviz
Mediolanum International Funds Ltd Raises Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK is Atle Fund Management AB's 4th Largest Position - MarketBeat
Principal Financial Group Inc. Decreases Stake in Merck & Co., Inc. $MRK - MarketBeat
Thrivent Financial for Lutherans Boosts Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Independent Advisor Alliance Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (MRK) joins BofA’s US 1 list - MSN
Merck & Co., Inc. (MRK) Joins BofA's "US 1 List" - Finviz
Merck & Co., Inc. (MRK) Joins BofA’s “US 1 List” - Insider Monkey
Cantor Fitzgerald Sees Deal Activity and Pipeline Progress as Key for Merck’s (MRK) Next Phase - Insider Monkey
Keybank National Association OH Trims Position in Merck & Co., Inc. $MRK - MarketBeat
Federated Hermes Inc. Sells 307,109 Shares of Merck & Co., Inc. $MRK - MarketBeat
National Pension Service Purchases 175,582 Shares of Merck & Co., Inc. $MRK - MarketBeat
Winnow Wealth LLC Purchases 12,091 Shares of Merck & Co., Inc. $MRK - MarketBeat
Centric Wealth Management Trims Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Technical Breakout Setup for Merck & Co. Inc. (NYSE:MRK) - Chartmill
Merck & Co., Inc. (NYSE:MRK) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
6.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):